<DOC>
	<DOCNO>NCT02360592</DOCNO>
	<brief_summary>This study multi-center , randomize , prospective , open-label Phase IV Clinical trial evaluate efficacy safety interferon alfa-2b therapy combinated interleukin 2 hepatitis B therapeutic vaccine versus interferon alfa-2b alone chronic hepatitis B patient entecavir achieve HBeAg seroclearance . Patients randomize one 3 group receive different antiviral treatment .</brief_summary>
	<brief_title>Combination Therapy With Interferon Plus Interleukin 2 Hepatitis B Vaccine Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Patients pretreated entecavir least one year , HBV ( Hepatitis B Virus ) DNA less 1000 copies/ml HBeAg seroclearance randomize one 3 group , receive Entecavir 0.5 mg po daily 72 week , Interferon alfa-2b 600wIU qod iH 48 week plus Entecavir 0.5mg qd po 8 week , Interferon alfa-2b 600wIU qod iH 48 week plus Entecavir 0.5mg qd po 8 week plus interleukin 2 25 wIU qod iH 12 week plus Hepatitis B Vaccine 60ug qm im 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Male female patient 18 65 year age ; 2 . Undergoing treatment entecavir least 1 year ; 3 . HBsAg ( + ) , HBeAg ( + ) , HBV DNA≥ 100000 copies/ml，ALT≥2 ULN ≤10 ULN receive entecavir treatment ; 4 . HBV DNA ≤1000 copies/mL ; 5 . HBeAg ( ) ; 6 . HBsAg ( + ) ; 7 . Negative urine serum pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose test drug ; 8 . Liver biopsy confirm without cirrhosis ( optional ) ; 9 . Agree participate study sign patient inform consent . 1 . Patients NAs resistance ; 2 . Other antiviral , antineoplastic immunomodulatory treatment ( include supra physiologic dose steroid radiation ) 6 month prior first dose randomize treatment ( except 7 day acyclovir herpetic lesion 1 month prior first administration randomize treatment ) . Patients expect need systemic antiviral therapy provide study time participation also exclude ; 3 . Women ongoing pregnancy breastfeeding ; 4 . Coinfection active hepatitis A , hepatitis C , hepatitis D ( Those hospital ability test ) and/or human immunodeficiency virus ( HIV ) ; 5 . ALT &gt; 10 ULN ; 6 . Evidence decompensated liver disease ( ChildPugh score &gt; 5 ) . ChildPugh &gt; 5 mean , one follow 6 condition meet , patient exclude : a. Serum albumin &lt; 3.5 g/L ; b. Prothrombin time &gt; 3 second prolong ; c. Serum bilirubin &gt; 34 μ mol/L ; d. History encephalopathy ; e. History variceal bleeding ; f. Ascites ; 7 . History evidence medical condition associate chronic liver disease viral hepatitis ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure , thalassemia ) ; 8 . Signs symptoms hepatocellular carcinoma , patient value alphafetoprotein &gt; 100 ng/mL exclude , unless stability ( le 10 % increase ) document least previous 3 month . Patients value &lt; 20 ng/mL &gt; 100 ng/mL may enrol , hepatic neoplasia exclude liver image ; 9 . Neutrophil count &lt; 1500 cells/mm3 platelet count &lt; 90,000 cells/mm3 screening ; 10 . Hemoglobin &lt; 11.5 g/dL female &lt; 12.5 g/dL men ; 11 . Serum creatinine level &gt; 1.5 ULN screening period . 12 . Phosphorus &lt; 0.65 mmol/L ; 13 . ANA &gt; 1:100 ; 14 . History severe psychiatric disease , especially depression . Severe psychiatric disease define treatment antidepressant medication major tranquilizer herapeutic dos major depression psychosis , respectively , least 3 month previous time history follow : suicidal attempt hospitalization psychiatric disease , period disability due psychiatric disease ; 15 . History severe seizure disorder current anticonvulsant use ; 16 . History immunologically mediate disease , ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , rheumatoid arthritis etc . ) ; 17 . History chronic pulmonary disease associate functional limitation ; 18 . Diseases IFN Nucleotides nucleoside suitable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>